391 related articles for article (PubMed ID: 27325420)
1. GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer.
Martinelli P; Carrillo-de Santa Pau E; Cox T; Sainz B; Dusetti N; Greenhalf W; Rinaldi L; Costello E; Ghaneh P; Malats N; Büchler M; Pajic M; Biankin AV; Iovanna J; Neoptolemos J; Real FX
Gut; 2017 Sep; 66(9):1665-1676. PubMed ID: 27325420
[TBL] [Abstract][Full Text] [Related]
2. GATA6-AS1 suppresses epithelial-mesenchymal transition of pancreatic cancer under hypoxia through regulating SNAI1 mRNA stability.
Zhou Y; Zhou X; Ben Q; Liu N; Wang J; Zhai Y; Bao Y; Zhou L
J Transl Med; 2023 Dec; 21(1):882. PubMed ID: 38057853
[TBL] [Abstract][Full Text] [Related]
3. The acinar regulator Gata6 suppresses KrasG12V-driven pancreatic tumorigenesis in mice.
Martinelli P; Madriles F; Cañamero M; Pau EC; Pozo ND; Guerra C; Real FX
Gut; 2016 Mar; 65(3):476-86. PubMed ID: 25596178
[TBL] [Abstract][Full Text] [Related]
4. GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer.
O'Kane GM; Grünwald BT; Jang GH; Masoomian M; Picardo S; Grant RC; Denroche RE; Zhang A; Wang Y; Lam B; Krzyzanowski PM; Lungu IM; Bartlett JMS; Peralta M; Vyas F; Khokha R; Biagi J; Chadwick D; Ramotar S; Hutchinson S; Dodd A; Wilson JM; Notta F; Zogopoulos G; Gallinger S; Knox JJ; Fischer SE
Clin Cancer Res; 2020 Sep; 26(18):4901-4910. PubMed ID: 32156747
[TBL] [Abstract][Full Text] [Related]
5. TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes.
Eyres M; Lanfredini S; Xu H; Burns A; Blake A; Willenbrock F; Goldin R; Hughes D; Hughes S; Thapa A; Vavoulis D; Hubert A; D'Costa Z; Sabbagh A; Abraham AG; Blancher C; Jones S; Verrill C; Silva M; Soonawalla Z; Maughan T; Schuh A; Mukherjee S; O'Neill E
Gastroenterology; 2021 Aug; 161(2):653-668.e16. PubMed ID: 33915173
[TBL] [Abstract][Full Text] [Related]
6. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
7. A GATA6-centred gene regulatory network involving HNFs and ΔNp63 controls plasticity and immune escape in pancreatic cancer.
Kloesch B; Ionasz V; Paliwal S; Hruschka N; Martinez de Villarreal J; Öllinger R; Mueller S; Dienes HP; Schindl M; Gruber ES; Stift J; Herndler-Brandstetter D; Lomberk GA; Seidler B; Saur D; Rad R; Urrutia RA; Real FX; Martinelli P
Gut; 2022 Apr; 71(4):766-777. PubMed ID: 33846140
[TBL] [Abstract][Full Text] [Related]
8. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition.
Ramaker RC; Hardigan AA; Gordon ER; Wright CA; Myers RM; Cooper SJ
BMC Cancer; 2021 May; 21(1):632. PubMed ID: 34049503
[TBL] [Abstract][Full Text] [Related]
9. EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of
Patil S; Steuber B; Kopp W; Kari V; Urbach L; Wang X; Küffer S; Bohnenberger H; Spyropoulou D; Zhang Z; Versemann L; Bösherz MS; Brunner M; Gaedcke J; Ströbel P; Zhang JS; Neesse A; Ellenrieder V; Singh SK; Johnsen SA; Hessmann E
Cancer Res; 2020 Nov; 80(21):4620-4632. PubMed ID: 32907838
[TBL] [Abstract][Full Text] [Related]
10. GATA6 activates Wnt signaling in pancreatic cancer by negatively regulating the Wnt antagonist Dickkopf-1.
Zhong Y; Wang Z; Fu B; Pan F; Yachida S; Dhara M; Albesiano E; Li L; Naito Y; Vilardell F; Cummings C; Martinelli P; Li A; Yonescu R; Ma Q; Griffin CA; Real FX; Iacobuzio-Donahue CA
PLoS One; 2011; 6(7):e22129. PubMed ID: 21811562
[TBL] [Abstract][Full Text] [Related]
11. GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma.
de Andrés MP; Jackson RJ; Felipe I; Zagorac S; Pilarsky C; Schlitter AM; Martinez de Villareal J; Jang GH; Costello E; Gallinger S; Ghaneh P; Greenhalf W; Knösel T; Palmer DH; Ruemmele P; Weichert W; Buechler M; Hackert T; Neoptolemos JP; Notta F; Malats N; Martinelli P; Real FX
Gut; 2023 Mar; 72(3):535-548. PubMed ID: 36109153
[TBL] [Abstract][Full Text] [Related]
12. The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer.
Duan K; Jang GH; Grant RC; Wilson JM; Notta F; O'Kane GM; Knox JJ; Gallinger S; Fischer S
Sci Rep; 2021 Jul; 11(1):14951. PubMed ID: 34294813
[TBL] [Abstract][Full Text] [Related]
13. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn.
Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y
Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of TGF-β signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models.
Hong E; Park S; Ooshima A; Hong CP; Park J; Heo JS; Lee S; An H; Kang JM; Park SH; Park JO; Kim SJ
Sci Rep; 2020 Feb; 10(1):2935. PubMed ID: 32076068
[TBL] [Abstract][Full Text] [Related]
15. TET1 downregulates epithelial-mesenchymal transition and chemoresistance in PDAC by demethylating CHL1 to inhibit the Hedgehog signaling pathway.
Li H; Jiang W; Liu XN; Yuan LY; Li TJ; Li S; Xu SS; Zhang WH; Gao HL; Han X; Wang WQ; Wu CT; Yu XJ; Xu HX; Liu L
Oncogene; 2020 Sep; 39(36):5825-5838. PubMed ID: 32753651
[TBL] [Abstract][Full Text] [Related]
16. GATA6 regulates expression of annexin A10 (ANXA10) associated with epithelial-mesenchymal transition of oral squamous cell carcinoma.
Takayama S; Morita Y; Nishimoto A; Nishimura J; Takebe K; Kishimoto S; Matsumiya-Matsumoto Y; Matsunaga K; Imai T; Uzawa N
Arch Oral Biol; 2022 Dec; 144():105569. PubMed ID: 36265396
[TBL] [Abstract][Full Text] [Related]
17. MiR-301a transcriptionally activated by HIF-2α promotes hypoxia-induced epithelial-mesenchymal transition by targeting TP63 in pancreatic cancer.
Zhang KD; Hu B; Cen G; Yang YH; Chen WW; Guo ZY; Wang XF; Zhao Q; Qiu ZJ
World J Gastroenterol; 2020 May; 26(19):2349-2373. PubMed ID: 32476798
[TBL] [Abstract][Full Text] [Related]
18. A nicotine-induced positive feedback loop between HIF1A and YAP1 contributes to epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma.
Ben Q; An W; Sun Y; Qian A; Liu J; Zou D; Yuan Y
J Exp Clin Cancer Res; 2020 Sep; 39(1):181. PubMed ID: 32894161
[TBL] [Abstract][Full Text] [Related]
19. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.
Zheng X; Carstens JL; Kim J; Scheible M; Kaye J; Sugimoto H; Wu CC; LeBleu VS; Kalluri R
Nature; 2015 Nov; 527(7579):525-530. PubMed ID: 26560028
[TBL] [Abstract][Full Text] [Related]
20. Upregulated long noncoding RNA LINC01296 indicates a dismal prognosis for pancreatic ductal adenocarcinoma and promotes cell metastatic properties by affecting EMT.
Yuan Q; Zhang Y; Feng L; Jiang Y
J Cell Biochem; 2019 Jan; 120(1):552-561. PubMed ID: 30203487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
